Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600211'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 7.87 Med: 20.15 Max: 24.58
Current: 17.38
During the past 13 years, Tibet Rhodiola Pharmaceutical Holding Co's highest Return-on-Tangible-Asset was 24.58%. The lowest was 7.87%. And the median was 20.15%.
SHSE:600211's Return-on-Tangible-Asset is ranked better than 91.76% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.98
vs SHSE:600211: 17.38
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Tibet Rhodiola Pharmaceutical Holding Co Return-on-Tangible-Asset Related Terms
Tibet Rhodiola Pharmaceutical Holding Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co Return-on-Tangible-Asset Chart
Tibet Rhodiola Pharmaceutical Holding Co Annual Data
SHSE:600211 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 20.08% mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Return-on-Tangible-Asset of 20.08% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. This is near median its historical median of 20.15. Over the past decade, Tibet Rhodiola Pharmaceutical Holding Co's Return-on-Tangible-Asset has ranged from 7.87 to 24.58. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #83 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Tibet Rhodiola Pharmaceutical Holding Co's Return-on-Tangible-Asset too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Return-on-Tangible-Asset of 20.08% is near median its 10-year median of 20.15. Over the past 10 years, this metric has ranged from a low of 7.87 to a high of 24.58. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.98. Tibet Rhodiola Pharmaceutical Holding Co's value of 20.08% is 573.8% above this industry median. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #83 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #83 out of 1007 companies for Return-on-Tangible-Asset. This places Tibet Rhodiola Pharmaceutical Holding Co in the top 8% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.98. Tibet Rhodiola Pharmaceutical Holding Co's value of 20.08% is 573.8% above this benchmark. Historically, Tibet Rhodiola Pharmaceutical Holding Co's own Return-on-Tangible-Asset has ranged from 7.87 to 24.58 over the past decade. While the company's 10-year median is 20.15 vs. the industry median of 2.98, Tibet Rhodiola Pharmaceutical Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.98, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current Return-on-Tangible-Asset of 20.08% is 573.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current Return-on-Tangible-Asset is 20.08%, which is near median its own 10-year median of 20.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥39.69, compared to a current price of ¥39.10 — trading 1.5% below its estimated fair value. The current Return-on-Tangible-Asset is 20.08%, which is near median its 10-year median of 20.15 and 573.8% above the Drug Manufacturers industry median of 2.98. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Return-on-Tangible-Asset is 20.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued.
The current stock price of ¥39.10 is trading 1.5% below its estimated GF Value™ of ¥39.69.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
Return-on-Tangible-Asset: 20.08% (near median its 10-year median of 20.15)
GF Value™: ¥39.69 vs. price of ¥39.10 (1.5% below fair value)
Industry Position: 573.8% above the Drug Manufacturers median (#83 of 1007)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
87GF Score
Get the complete analysis for SHSE:600211
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
